← Back to Screener
US Stock Screener
HomeScreensNewsWatchlist
...

POMDOCTOR Ltd (POM) 10-Year Financial Performance & Capital Metrics

POM • • Industrial / General
HealthcarePharmaceuticalsDigital Health & TelemedicineOnline Pharmacy Platforms
AboutPomdoctor Limited, through its subsidiaries, offers an online B2C portal to sell pharmaceutical products. The company develops an online medical services platform for chronic diseases in China. The company focuses on chronic disease management and pharmaceutical services and offers platform for medical services, which connects patients to doctors and pharmaceutical products. The company's business primarily consists of internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. The company was founded in 2010 and is headquartered in Guangzhou, China.Show more
  • Revenue $343M +12.4%
  • EBITDA -$26M -15.9%
  • Net Income -$143M +1.4%
  • EPS (Diluted) -1.21 +1.6%
  • Gross Margin 13.92% +9.6%
  • EBITDA Margin -7.49% -3.1%
  • Operating Margin -7.53% -3.2%
  • Net Margin -41.85% +12.2%
  • ROE -
  • ROIC -
  • Debt/Equity -
  • Interest Coverage -1.99 -23.8%
Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

  • ✓Efficient asset utilization: 7.4x turnover

✗Weaknesses

  • ✗Negative free cash flow
  • ✗Weak momentum: RS Rating 11 (bottom 11%)
  • ✗Low quality earnings: Net income not backed by cash flow
  • ✗Trading more than 30% below 52-week high

* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-
5Y-
3Y16.73%
TTM-

Profit (Net Income) CAGR

10Y-
5Y-
3Y-
TTM-

EPS CAGR

10Y-
5Y-
3Y-
TTM-

ROCE

10Y Avg-
5Y Avg-
3Y Avg-
Latest-

Peer Comparison

Online Pharmacy Platforms
Select Columns
Size & Scale
Valuation
Per Share
Growth
Profitability
Quality & Returns
Safety & Leverage
TTM Growth
Famous Investor Metrics
Dividends
Latest Quarter
Momentum & Returns
Total Return (DRIP)
Technical
Volume & Trading
Shares & Dilution
Sector-Specific
NameMarket CapCurrent PriceP/E RatioRevenue Growth 1YNet MarginROEFCF YieldDebt/Equity
POMPOMDOCTOR Ltd32.72M0.31-0.2512.37%-41.85%

Profit & Loss

Dec 2021Dec 2022Dec 2023Dec 2024
Sales/Revenue+215.38M245.22M304.85M342.56M
Revenue Growth %-0.14%0.24%0.12%
Cost of Goods Sold+162.88M190.36M266.13M294.86M
COGS % of Revenue0.76%0.78%0.87%0.86%
Gross Profit+52.51M54.86M38.72M47.69M
Gross Margin %0.24%0.22%0.13%0.14%
Gross Profit Growth %-0.04%-0.29%0.23%
Operating Expenses+132.18M58.46M60.97M73.49M
OpEx % of Revenue0.61%0.24%0.2%0.21%
Selling, General & Admin102.95M54.87M55.99M68.24M
SG&A % of Revenue0.48%0.22%0.18%0.2%
Research & Development4.28M3.59M3.37M3M
R&D % of Revenue0.02%0.01%0.01%0.01%
Other Operating Expenses24.94M01.61M2.24M
Operating Income+-79.67M-3.59M-22.25M-25.79M
Operating Margin %-0.37%-0.01%-0.07%-0.08%
Operating Income Growth %-0.95%-5.19%-0.16%
EBITDA+-58.35M-3.81M-22.14M-25.66M
EBITDA Margin %-0.27%-0.02%-0.07%-0.07%
EBITDA Growth %-0.93%-4.81%-0.16%
D&A (Non-Cash Add-back)21.32M0112.09K134.51K
EBIT-79.89M-3.81M-23.1M-24.4M
Net Interest Income+-16.29M-16.02M-13.85M-12.96M
Interest Income0000
Interest Expense16.29M16.02M13.85M12.96M
Other Income/Expense-16.51M-16.24M-14.7M-11.57M
Pretax Income+-96.18M-19.83M-36.95M-37.37M
Pretax Margin %-0.45%-0.08%-0.12%-0.11%
Income Tax+0000
Effective Tax Rate %1.96%6.33%3.93%3.84%
Net Income+-188.4M-125.51M-145.39M-143.36M
Net Margin %-0.87%-0.51%-0.48%-0.42%
Net Income Growth %-0.33%-0.16%0.01%
Net Income (Continuing)-96.18M-19.83M-36.95M-37.37M
Discontinued Operations0000
Minority Interest71.66M76.66M158.64M168.69M
EPS (Diluted)+-1.59-1.06-1.23-1.21
EPS Growth %-0.33%-0.16%0.02%
EPS (Basic)-1.59-1.06-1.23-1.21
Diluted Shares Outstanding118.44M118.44M118.44M118.44M
Basic Shares Outstanding118.44M118.44M118.44M118.44M
Dividend Payout Ratio----

Balance Sheet

Dec 2021Dec 2022Dec 2023Dec 2024
Total Current Assets+18.43M47.74M59.42M37.5M
Cash & Short-Term Investments2.17M2.49M6.72M7.65M
Cash Only2.17M2.49M6.72M7.65M
Short-Term Investments0000
Accounts Receivable739.57K27.25M32.39M14.97M
Days Sales Outstanding1.2540.5738.7815.95
Inventory8.12M8.2M12.69M9.17M
Days Inventory Outstanding18.1915.7117.4111.35
Other Current Assets0159.9K88.07K0
Total Non-Current Assets+877.63K877.63K6.89M8.73M
Property, Plant & Equipment00595.87K461.36K
Fixed Asset Turnover--511.61x742.49x
Goodwill0000
Intangible Assets0000
Long-Term Investments500K500K00
Other Non-Current Assets377.63K377.63K6.29M8.27M
Total Assets+19.31M48.62M66.31M46.23M
Asset Turnover11.15x5.04x4.60x7.41x
Asset Growth %-1.52%0.36%-0.3%
Total Current Liabilities+109.39M143.61M172M179.15M
Accounts Payable30.41M43.35M41.69M25.35M
Days Payables Outstanding68.1483.1257.1831.38
Short-Term Debt23.38M29.45M55.41M72.95M
Deferred Revenue (Current)1000K1000K1000K1000K
Other Current Liabilities0002.08M
Current Ratio0.17x0.33x0.35x0.21x
Quick Ratio0.09x0.28x0.27x0.16x
Cash Conversion Cycle-48.69-26.84-0.99-4.07
Total Non-Current Liabilities+1.69B1.8B1.86B1.96B
Long-Term Debt312.51M318.93M355.4M365.09M
Capital Lease Obligations2.94M11.44M1.22M1.67M
Deferred Tax Liabilities0000
Other Non-Current Liabilities1.37B1.47B1.5B1.6B
Total Liabilities1.8B1.95B2.03B2.14B
Total Debt+341.26M361.24M413.29M441.1M
Net Debt339.09M358.76M406.58M433.45M
Debt / Equity----
Debt / EBITDA----
Net Debt / EBITDA----
Interest Coverage-4.89x-0.22x-1.61x-1.99x
Total Equity+-1.78B-1.9B-1.96B-2.09B
Equity Growth %--0.07%-0.03%-0.07%
Book Value per Share-15.01-16.02-16.56-17.69
Total Shareholders' Equity-1.85B-1.97B-2.12B-2.26B
Common Stock2.79K2.79K4.4K4.4K
Retained Earnings-1.85B-1.97B-2.12B-2.26B
Treasury Stock0000
Accumulated OCI000-5.23K
Minority Interest71.66M76.66M158.64M168.69M

Cash Flow

Dec 2021Dec 2022Dec 2023Dec 2024
Cash from Operations+-15.68M-22.02M-45.8M-16.13M
Operating CF Margin %-0.07%-0.09%-0.15%-0.05%
Operating CF Growth %--0.4%-1.08%0.65%
Net Income-96.18M-19.83M-36.95M-37.37M
Depreciation & Amortization21.32M0112.09K134.51K
Stock-Based Compensation0000
Deferred Taxes0000
Other Non-Cash Items24.05M-774.45K3.6M3.57M
Working Capital Changes35.14M-1.41M-12.56M17.53M
Change in Receivables-917.34K-26.75M-4.45M16.45M
Change in Inventory-1.59M-77.56K-5M3.03M
Change in Payables5.43M12.94M-1.66M-16.34M
Cash from Investing+-500K0-111.89K-33.37K
Capital Expenditures00-111.89K-37.77K
CapEx % of Revenue--0%0%
Acquisitions----
Investments----
Other Investing0004.4K
Cash from Financing+5.44M22.49M50.07M17.02M
Debt Issued (Net)----
Equity Issued (Net)----
Dividends Paid0000
Share Repurchases----
Other Financing00-2.28M0
Net Change in Cash----
Free Cash Flow+-15.68M-22.02M-45.91M-16.17M
FCF Margin %-0.07%-0.09%-0.15%-0.05%
FCF Growth %--0.4%-1.09%0.65%
FCF per Share-0.13-0.19-0.39-0.14
FCF Conversion (FCF/Net Income)0.08x0.18x0.31x0.11x
Interest Paid4.05M3.24M2.39M2.74M
Taxes Paid0000

Key Ratios

Metric2021202220232024
Gross Margin24.38%22.37%12.7%13.92%
Net Margin-87.47%-51.18%-47.69%-41.85%
Interest Coverage-4.89x-0.22x-1.61x-1.99x
FCF Conversion0.08x0.18x0.31x0.11x
Revenue Growth-13.85%24.32%12.37%

Frequently Asked Questions

Growth & Financials

POMDOCTOR Ltd (POM) reported $342.6M in revenue for fiscal year 2024. This represents a 59% increase from $215.4M in 2021.

POMDOCTOR Ltd (POM) grew revenue by 12.4% over the past year. This is steady growth.

POMDOCTOR Ltd (POM) reported a net loss of $143.4M for fiscal year 2024.

Dividend & Returns

POMDOCTOR Ltd (POM) had negative free cash flow of $16.2M in fiscal year 2024, likely due to heavy capital investments.

VCP Scanner

Find stocks. Verify deeply. Act with conviction.

Patterns find ideas. Fundamentals build conviction.

Data updated daily

Quick Links

  • Home
  • Screens
  • Valuation
  • Compare
  • Total Return
  • News
  • Insights
  • Methodology
  • How It Works
  • Profile

Popular Screens

  • VCP Hot
  • VCP Warm
  • Value Screens
  • Growth Screens
  • Momentum Screens
  • Technical Screens
  • Quality Screens

Community

  • Twitter
  • Get Early Access
© 2026 VCP Scanner. All rights reserved.
Made with ❤️ for investors
Not financial advice. Do your own research.